leisure time -WSS

leisure time

author：comprehensive 2025-10-01 04:32:44 - browse：8

Obesity conference attendees with a pink and blue Wegovy sign hanging from the ceiling above. -- obesity coverage from STAT — Wegovy, the obesity drug, was inescapable at the ObesityWeek conference in Dallas. Elaine Chen

DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and Eli Lilly are displaying more than a dozen studies that together carry the message: Our blockbuster weight loss treatments will be worth it for society.

But experts point out that much of this company-funded research does not include the cost of the drugs themselves, which sell at more than $10,000 per year in the U.S. and are meant to be taken indefinitely.

The two major pharmaceutical companies have seen interest skyrocket for their GLP-1-based drugs like Ozempic, Wegovy, and Mounjaro, a new generation of medications that can cut substantial amounts of weight. But insurance plans have been slow to grant wide access to obesity treatments, concerned that the vast amount of people eligible to take them, along with their high price, could lead to significant financial strain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Information blocking fines are now fair game in health care

knowledge

WSS

FDA panel to weigh safety of artificial wombs for preterm births

Patients, doctors press FTC to beef up hospital merger scrutiny

PBMs drew scrutiny in House hearing — and so did pharma

The unintended consequences of overturning Roe v. Wade

Chamber of Commerce, DOJ clash in court over drug prices

Fed up with FDA, ALS advocates consider a take

leisure time

leisure time

explore

The cancer drug shortage isn’t new — and neither are the solutions

Why the Crimean Bridge is key to Russia's war in Ukraine

DIEP, the 'gold standard' of breast reconstruction, is under threat

FDA panel to weigh safety of artificial wombs for preterm births

The high cost of giving birth even with insurance

Akili changes sales model for its ADHD video game treatment

Cancer drug shortages should be causing more outrage

Stanford updates investigation of president’s past research

Continuity nursing helped my family in our darkest PICU moments

People with substance use disorder deserve online privacy

hotspot

Chamber of Commerce, DOJ clash in court over drug prices

The kidney, in all its complexity, is captured in a new atlas

PBMs drew scrutiny in House hearing — and so did pharma

Why the quest to eradicate polio has stumbled

Akili changes sales model for its ADHD video game treatment

Trump got a 'target letter.' What is one and what does it mean?

hotspot

knowledge

entertainment

entertainment